Top

World Journal of Surgical Oncology

Published in:

Open Access 01-12-2014 | Research

A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

Authors: Seung Taek Lim, Jong Han Yu, Heung Kyu Park, Byung In Moon, Byung Kyun Ko, Young Jin Suh

Published in: World Journal of Surgical Oncology | Issue 1/2014

Abstract

Background

To investigate the clinicopathological characteristics and the survival outcomes of invasive lobular carcinoma (ILC) patients compared to invasive ductal carcinoma (IDC) patients according to their molecular subtype.

Methods

We compared the clinicopathological characteristics, breast cancer-specific survival (BCSS) and overall survival (OS) between patients with IDC (n = 14,547) and ILC (n = 528).

Results

The ILC presented with a larger tumor size, more advanced cancer stage, increased rate of hormonal receptor positivity, human epidermal growth factor 2 (HER2) negativity and mastectomy than the IDC. The ILC patients more frequently presented with the luminal A subtype, whereas the IDC patients more frequently presented with the luminal B, HER2-overexpression, or triple negative subtype. The BCSS and OS were not significantly different between the IDC and ILC for each molecular subtype.

Conclusions

Similar to IDC patients, molecular subtype should be considered when determining the prognosis and treatment regimen for ILC patients.

Available only for authorised users

Pestalozzi BC: Brain metastases and subtypes of breast cancer. Ann Oncol. 2009, 20: 803-805. 10.1093/annonc/mdp246.CrossRefPubMed

Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ, Robertson JF, Blamey R, Gee J, Nicholson RI, Lee AH, Ellis IO: Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer. 2008, 44: 73-83. 10.1016/j.ejca.2007.10.009.CrossRefPubMed

Li CI, Anderson BO, Daling JR, Moe RE: Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA. 2003, 289: 1421-1424. 10.1001/jama.289.11.1421.CrossRefPubMed

Li CI, Anderson BO, Porter P, Holt SK, Daling JR, Moe RE: Changing incidence rate of invasive lobular breast carcinoma among older women. Cancer. 2000, 88: 2561-2569. 10.1002/1097-0142(20000601)88:11<2561::AID-CNCR19>3.0.CO;2-X.CrossRefPubMed

Devesa SS, Blot WJ, Stone BJ, Miller BA, Tarone RE, Jr Fraumeni JF: Recent cancer trends in the United Stated. J Natl Cancer Inst. 1995, 87: 175-182. 10.1093/jnci/87.3.175.CrossRefPubMed

Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L, Cortese G, Farina M, Vitelli C: Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period. Ann SurgOncol. 2012, 19: 1107-1114.

Jayasinghe UW, Bilous AM, Boyages J: Is survival from infiltrating lobular carcinoma of the breast different from that of infiltrating ductal carcinoma?. Breast J. 2007, 13: 479-485. 10.1111/j.1524-4741.2007.00468.x.CrossRefPubMed

Ashikari R, Huvos AG, Urban JA, Robbins GF: Infiltrating lobular carcinoma of the breast. Cancer. 1973, 31: 110-116. 10.1002/1097-0142(197301)31:1<110::AID-CNCR2820310115>3.0.CO;2-V.CrossRefPubMed

Davis RP, Nora PF, Kooy RG, Hines JR: Experience with lobular carcinoma of the breast. Emphasis on recent aspects of management. Arch Surg. 1979, 114: 185-188. 10.1001/archsurg.1979.01370260075012.CrossRef

10.

Toikkanen S, Pylkkanen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer. 1997, 76: 1234-1240. 10.1038/bjc.1997.540.PubMedCentralCrossRefPubMed

11.

Gonzalez-Angulo AM, Sahin A, Krishnamurthy S, Yang Y, Kau SW, Hortobagyi GN, Cristofanilli M: Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma. Clin Breast Cancer. 2006, 7: 396-400. 10.3816/CBC.2006.n.056.CrossRefPubMed

12.

Conford EJ, Wilson AR, Athanassiou E, Galea M, Ellis IO, Elston CW, Blamey RW: Mammographic features of invasive lobular and invasive ductal carcinoma of the breast: a comparative analysis. Br J Radiol. 1995, 68: 450-453. 10.1259/0007-1285-68-809-450.CrossRef

13.

Dixon JM, Anderson TJ, Page DL, Lee D, Duffy SW, Stewart HJ: Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg. 1983, 70: 513-516. 10.1002/bjs.1800700902.CrossRefPubMed

14.

Lesser ML, Rosen PP, Kinne DW: Multicentricity and bilaterality in invasive breast carcinoma. Surgery. 1982, 91: 234-240.PubMed

15.

Ko SS, Korean Breast Cancer Society: Chronological changing patterns of clinical characteristics of Korean breast cancer patients during 10 years (1996 to 2006) using nationwide breast cancer registration on-line program: biannual update. J SurgOncol. 2008, 98: 318-323.

16.

Lee JH, Park S, Park HS, Park BW: Clinicopathological features of infiltrating lobular carcinomas comparing with infiltrating ductal carcinomas: a case control study. World J SurgOncol. 2010, 8: 34-CrossRef

17.

Moon HG, Han W, Noh DY: Underweight and breast cancer recurrence and death: a report from the Korean breast cancer society. J ClinOncol. 2009, 10: 5899-5905.CrossRef

18.

Arpino G, Bardou VJ, Clark GM, Elledge RM: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004, 6: R149-R156. 10.1186/bcr767.PubMedCentralCrossRefPubMed

19.

Turin W, Voogd AC, Vreugdenhil G, Van der Heiden-van der Loo M, Siesling S, Roumen RM: Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol. 2012, 23: 2859-2865. 10.1093/annonc/mds180.CrossRef

20.

Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A, International Breast Cancer Study Group: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J ClinOncol. 2008, 26: 3006-3014. 10.1200/JCO.2007.14.9336.CrossRef

21.

Wasif N, Maggard MA, Ko CY, Giuliano AE: Invasive lobular versus ductal breast cancer: a stage-matched comparison of outcomes. Ann SurgOncol. 2010, 17: 1862-1869.

22.

Yeatman TJ, Cantor AB, Smith TJ, Smith SK, Reintgen SD, Miller MS, Ku NN, Baekey PA, Cox CE: Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg. 1995, 222: 549-559. 10.1097/00000658-199522240-00012.PubMedCentralCrossRefPubMed

23.

Veltman J, Boetes C, van Die L, Bult P, Blickman JG, Barentsz JO: Mammographic detection and staging of invasive lobular carcinoma. Clin Imaging. 2006, 30: 94-98. 10.1016/j.clinimag.2005.09.021.CrossRefPubMed

24.

Petrausch U, Pestalozzi BC: Distinct clinical and prognostic features of invasive lobular breast cancer. Breast Dis. 2008–2009, 30: 39-44.

25.

Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N, Montagna E, Dellapasqua S, Veronesi P, Galimberti V, Luini A, Goldhirsch A, Colleoni M, Viale G: Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat. 2012, 133: 713-723. 10.1007/s10549-012-2002-z.CrossRefPubMed

26.

Cao AY, Huang L, Wu J, Lu JS, Liu GY, Shen ZZ, Shao ZM, Di GH: Tumor characteristics and the clinical outcome of invasive lobular carcinoma compared to infiltrating ductal carcinoma in a Chinese population. World J SurgOncol. 2012, 10: 152-CrossRef

27.

Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B, Reis-Filho JS: The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol. 2010, 220: 45-57. 10.1002/path.2629.CrossRefPubMed

28.

André S, Tomás AR, Fonseca R: Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the reference laboratory of Lisbon. Acta Med Port. 2005, 18: 417-422.PubMed

29.

Moerland E, van Hezik RL, van der ATC, van Beek MW, van den Brule AJ: Detection of HER2 amplification in breast carcinomas: comparison of Multiplex Ligation-dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with automated spot counting. Cell Oncol. 2006, 28: 151-159.PubMed

30.

Bouvet M, Ollila DW, Hunt KK, Babiera GV, Spitz FR, Giuliano AE, Strom EA, Ames FC, Ross MI, Singletary SE: Role of conservation therapy for invasive lobular carcinoma of the breast. Ann SurgOncol. 1997, 4: 650-654.

31.

Sastre-Garau X, Jouve M, Asswlain B, Vincent-Salomon A, Beuzeboc P, Dorval T, Durand JC, Fourguet A, Pouillart P: Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996, 77: 113-120. 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8.CrossRefPubMed

32.

Salvadori B, Biganzoli E, Veronesi P, Saccozzi R, Rilke F: Conservative surgery for infiltrating lobular breast carcinoma. Br J Surg. 1997, 84: 106-109. 10.1002/bjs.1800840139.CrossRefPubMed

33.

Peiro G, Bornstein BA, Connolly JL, Gelman R, Hetelekidis S, Nixon AJ, Recht A, Silver B, Harris JR, Schnitt SJ: The influence of infiltrating lobular carcinoma on the outcome of patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2000, 59: 49-54. 10.1023/A:1006384407690.CrossRefPubMed

34.

Fritz P, Klenk S, Goletz S, Gerteis A, Simon W, Brinkmann F, Heidemann E, Lutttgen E, Ott G, Alscher MD, Schwab M, Dippon J: Clinical impacts of histological subtyping primary breast cancer. Anticancer Res. 2010, 30: 5137-5144.PubMed

35.

Metzger-Filho O, Procter M, de Azambuja E, Leyland-Jones B, Gelber RD, Dowsett M, Loi S, Saini KS, Cameron D, Untch M, Smith I, Gianni L, Baselga J, Jackisch C, Bell R, Sotiriou C, Viale G, Piccart-Gebhart M: Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. J ClinOncol. 2013, 31: 1954-1960. 10.1200/JCO.2012.46.2440.CrossRef

Title: A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population
Authors: Seung Taek Lim
Jong Han Yu
Heung Kyu Park
Byung In Moon
Byung Kyun Ko
Young Jin Suh
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-12-56

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A comparison of the clinical outcomes of patients with invasive lobular carcinoma and invasive ductal carcinoma of the breast according to molecular subtype in a Korean population

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma

Combined ultrasonic aspiration and saline-linked radiofrequency precoagulation: a step toward bloodless liver resection without the need of liver inflow occlusion: analysis of 313 consecutive patients

Percutaneous transhepatic and endoscopic biliary drainage for malignant biliary tract obstruction: a meta-analysis

Postoperative hemorrhage in an elderly patient with a glioblastoma multiform and a calcified chronic subdural hematoma

CD40 mutant expression and its clinical significance to prognosis in gastric cancer patients

RETRACTED ARTICLE: Clinico-histopathologic and outcome features of cutaneous infundibular keratinizing acanthoma: a case report and literature review